Schneck D W, Sprouse J S, Shiroff R A, Vary J E, DeWitt F O, Hayes A H
Pharmacology. 1979;18(1):34-41. doi: 10.1159/000137227.
The effect of isoniazid (INH) and procainamide (PA) on each other's acetylation pathway was studied in 7 normal subjects (3 rapid acetylators, 3 slow acetylators, 1 of indeterminate phenotype). Oral PA (6 mg/kg) was administered every 4 h for a total of seven doses. Following the final dose subjects received a single 300-mg oral dose of INH. Analysis of the parent drugs and their acetylated metabolites in plasma and urine revealed no effect on the acetylation of either drug. In 2 subjects (1 rapid, 1 slow acetylator) increasing doses of PA were given and the effect on INH (300 mg) acetylation measured. High mean circulating levels of PA (7.1 microgram/ml) appeared to inhibit acetylation of INH in the rapid acetylator whereas a mean PA plasma level of 8.6 microgram/ml had no effect on INH acetylation in the slow acetylator. However, the results from this study suggest that alterations of INH acetylation by PA are unlikely to be of clinical significance.
在7名正常受试者(3名快速乙酰化者、3名慢速乙酰化者、1名表型不确定者)中研究了异烟肼(INH)和普鲁卡因胺(PA)对彼此乙酰化途径的影响。每4小时口服PA(6mg/kg),共服用7剂。在最后一剂之后,受试者接受单次300mg口服剂量的INH。对血浆和尿液中的母体药物及其乙酰化代谢产物进行分析,结果显示对两种药物的乙酰化均无影响。在2名受试者(1名快速乙酰化者、1名慢速乙酰化者)中给予递增剂量的PA,并测定其对INH(300mg)乙酰化的影响。较高的PA平均循环水平(7.1μg/ml)似乎抑制了快速乙酰化者中INH的乙酰化,而PA血浆平均水平8.6μg/ml对慢速乙酰化者中INH的乙酰化没有影响。然而,该研究结果表明,PA对INH乙酰化的改变不太可能具有临床意义。